Literature DB >> 15913510

Managing Functional Disturbances in Patients with Inflammatory Bowel Disease.

Philip M Ginsburg1, Theodore M Bayless.   

Abstract

Functional disturbances occur in approximately 10% to 15% of the general population and in a similar percentage of patients with inflammatory bowel disease (IBD). Because overlapping irritable bowel syndrome (IBS) is so common, one of the most important interventions a clinician can make is recognizing its existence. This requires a thorough understanding of underlying pathophysiologic processes. Differentiating among the causes of symptoms is especially significant in a minority of patients mislabeled as having 'refractory IBD.' Escalating therapy directed at disease activity may have no effect on functional symptoms other than to reinforce their presence. Treatment of IBS in patients with IBD is similar to that of the general population. The cornerstone of treatment is establishing a constructive doctor-patient relationship. Initial therapy usually involves a conservative approach that includes patient education and diet and lifestyle modifications. Pharmacologic treatment is individualized and generally directed at the predominant symptoms. Options may broadly include antispasmodics, antidiarrheals, and antidepressants, either alone or in combination. Psychosocial therapies have shown to be beneficial in selected individuals.

Entities:  

Year:  2005        PMID: 15913510     DOI: 10.1007/s11938-005-0013-0

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  35 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

2.  Rectosigmoid motility in patients with quiescent and active ulcerative colitis.

Authors:  V Loening-Baucke; A M Metcalf; S Shirazi
Journal:  Am J Gastroenterol       Date:  1989-01       Impact factor: 10.864

3.  A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Authors:  M Camilleri; W Y Chey; E A Mayer; A R Northcutt; A Heath; G E Dukes; D McSorley; A M Mangel
Journal:  Arch Intern Med       Date:  2001-07-23

4.  Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study.

Authors:  Sally D Parry; Rosamund Stansfield; Diana Jelley; Wendy Gregory; Elizabeth Phillips; J Roger Barton; Mark R Welfare
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

Review 5.  Pharmacologic therapy for the irritable bowel syndrome.

Authors:  Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

6.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

7.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

Authors:  K A Gwee; J C Graham; M W McKendrick; S M Collins; J S Marshall; S J Walters; N W Read
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

Review 8.  Is the irritable gut an inflamed gut?

Authors:  S M Collins
Journal:  Scand J Gastroenterol Suppl       Date:  1992

9.  Functional bowel disorders in apparently healthy people.

Authors:  W G Thompson; K W Heaton
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

10.  5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.

Authors:  J R Grider; A E Foxx-Orenstein; J G Jin
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more
  4 in total

Review 1.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

2.  Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.

Authors:  Hrishikesh Samant; Devendra Desai; Philip Abraham; Anand Joshi; Tarun Gupta; Alpa Dherai; Tester Ashavaid
Journal:  Indian J Gastroenterol       Date:  2015-11-21

3.  Antidepressants and inflammatory bowel disease: a systematic review.

Authors:  Antonina A Mikocka-Walus; Deborah A Turnbull; Nicole T Moulding; Ian G Wilson; Jane M Andrews; Gerald J Holtmann
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-09-20

4.  Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study.

Authors:  Wan-Tzu Lin; Yi-Jun Liao; Yen-Chun Peng; Chung-Hsin Chang; Ching-Heng Lin; Hong-Zen Yeh; Chi-Sen Chang
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.